BR112022008039A2 - Compostos de 4-amino-imidazoquinolina e usos relacionados - Google Patents
Compostos de 4-amino-imidazoquinolina e usos relacionadosInfo
- Publication number
- BR112022008039A2 BR112022008039A2 BR112022008039A BR112022008039A BR112022008039A2 BR 112022008039 A2 BR112022008039 A2 BR 112022008039A2 BR 112022008039 A BR112022008039 A BR 112022008039A BR 112022008039 A BR112022008039 A BR 112022008039A BR 112022008039 A2 BR112022008039 A2 BR 112022008039A2
- Authority
- BR
- Brazil
- Prior art keywords
- amino
- disclosed
- allergic disease
- related uses
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
COMPOSTOS DE 4-AMINO-IMIDAZOQUINOLINA E USOS RELACIONADOS. São divulgados compostos de 4-amino-imidazoquinolina e usos relacionados. Os compostos da invenção são receptores tipo Toll 7 (TLR7) e agonistas duplos de TLR8, que exibem atividades na indução da expressão de IL-12 e IP-10 sem superindução de IL-6. Os agonistas duplos de TLR 7/8 são medicamentos potencialmente úteis como modificadores da resposta imune. É divulgado o uso de um composto ou sal relacionado, de acordo com a invenção, na fabricação de um medicamento para tratamento de uma doença ou condição em que a ativação de TLR7 e/ou TLR8 proporciona benefícios para um sujeito em necessidade. É divulgado, ainda, um composto ou uma composição farmacêutica para uso no tratamento de uma infecção viral, câncer e/ou uma doença alérgica, ou para uso na ativação de respostas imunes que são eficazes contra uma infecção viral, um tumor e/ou uma doença alérgica em um sujeito em necessidade.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962927354P | 2019-10-29 | 2019-10-29 | |
| PCT/US2020/056515 WO2021086689A1 (en) | 2019-10-29 | 2020-10-20 | 4-amino-imidazoquinoline compounds and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022008039A2 true BR112022008039A2 (pt) | 2022-07-12 |
Family
ID=75715560
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022008039A BR112022008039A2 (pt) | 2019-10-29 | 2020-10-20 | Compostos de 4-amino-imidazoquinolina e usos relacionados |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220411421A1 (pt) |
| EP (2) | EP4051270B1 (pt) |
| JP (1) | JP7773011B2 (pt) |
| KR (1) | KR20220091528A (pt) |
| CN (1) | CN114599360A (pt) |
| AU (1) | AU2020372832B2 (pt) |
| BR (1) | BR112022008039A2 (pt) |
| ES (1) | ES3075791T3 (pt) |
| TW (1) | TWI921313B (pt) |
| WO (1) | WO2021086689A1 (pt) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250025447A1 (en) * | 2021-11-03 | 2025-01-23 | Regents Of The University Of Minnesota | Toll-like receptor agonists and antagonists and uses thereof |
| CN116731015B (zh) * | 2023-05-18 | 2024-09-27 | 深圳威科森生物医药科技有限公司 | 咪唑并喹啉化合物及其制备方法、应用和组合物 |
| KR20250019209A (ko) | 2023-07-31 | 2025-02-10 | 건국대학교 글로컬산학협력단 | 니트로퓨라존 또는 니트로퓨란토인을 유효성분으로 하는 알레르기 질환 예방 또는 치료용 약학적 조성물 |
| CN117800965A (zh) * | 2023-12-28 | 2024-04-02 | 南方医科大学 | 2-氨基-咪唑并喹啉衍生化合物及其制备方法和用途 |
| CN119215159A (zh) * | 2024-09-24 | 2024-12-31 | 深圳市格茵莱生物科技有限公司 | 树突状细胞多抗原负载免疫治疗方法 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5266575A (en) * | 1991-11-06 | 1993-11-30 | Minnesota Mining And Manufacturing Company | 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines |
| US6664265B2 (en) * | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Amido ether substituted imidazoquinolines |
| UA74852C2 (en) | 2000-12-08 | 2006-02-15 | 3M Innovative Properties Co | Urea-substituted imidazoquinoline ethers |
| US6677348B2 (en) * | 2000-12-08 | 2004-01-13 | 3M Innovative Properties Company | Aryl ether substituted imidazoquinolines |
| JP2006513212A (ja) * | 2002-12-20 | 2006-04-20 | スリーエム イノベイティブ プロパティズ カンパニー | アリール／ヘタリール置換されたイミダゾキノリン |
| WO2006009832A1 (en) * | 2004-06-18 | 2006-01-26 | 3M Innovative Properties Company | Substituted imidazo ring systems and methods |
| WO2006028962A2 (en) * | 2004-09-02 | 2006-03-16 | 3M Innovative Properties Company | 1-alkoxy 1h-imidazo ring systems and methods |
| EP1850849A2 (en) * | 2005-02-23 | 2007-11-07 | Coley Pharmaceutical Group, Inc. | Method of preferentially inducing the biosynthesis of interferon |
| KR101606219B1 (ko) * | 2008-03-24 | 2016-03-24 | 4에스체 악티엔게젤샤프트 | 신규 치환된 이미다조퀴놀린 |
| EP2471548A1 (de) * | 2010-12-28 | 2012-07-04 | Apeiron Biologics AG | siRNA gegen Cbl-b und optional IL2 und IL12 zur Verwendung in der Behandlung von Krebs |
| US8728486B2 (en) | 2011-05-18 | 2014-05-20 | University Of Kansas | Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds |
| EP3153180A1 (en) * | 2011-06-03 | 2017-04-12 | 3M Innovative Properties Company | Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom |
| WO2014201245A1 (en) * | 2013-06-12 | 2014-12-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Tlr-9 agonist with tlr-7 and/or tlr-8 agonist for treating tumors |
| ES2804101T3 (es) * | 2014-04-22 | 2021-02-03 | Hoffmann La Roche | Compuestos de 4-amino-imidazoquinolina |
| US9884866B2 (en) | 2014-09-08 | 2018-02-06 | Regents Of The University Of Minnesota | Immunomodulators and immunomodulator conjugates |
| CN106943598A (zh) * | 2016-01-07 | 2017-07-14 | 博笛生物科技（北京）有限公司 | 用于治疗肿瘤的抗-her2组合 |
| WO2018175854A1 (en) * | 2017-03-23 | 2018-09-27 | The Children's Medical Center Corporation | Methods and compositions relating to adjuvants |
| EP4257198A3 (en) | 2017-08-22 | 2023-10-18 | Dynavax Technologies Corporation | Alkyl chain modified imidazoquinoline derivatives as tlr7/8 agonists and uses thereof |
| WO2019048036A1 (en) | 2017-09-06 | 2019-03-14 | Biontech Ag | SUBSTITUTED IMIDAZOQUINOLINES |
| EP4306523A3 (en) * | 2018-09-07 | 2024-01-24 | Birdie Biopharmaceuticals, Inc. | Imidazoquinoline compounds and uses thereof |
| EP3917926B1 (en) | 2019-02-01 | 2025-10-01 | Canwell Biotech Limited | Imidazoquinoline amine derivatives, pharmaceutical composition, use thereof |
| EP3980080A1 (en) | 2019-06-10 | 2022-04-13 | Sutro Biopharma, Inc. | Immunomodulator antibody drug conjugates and uses thereof |
-
2020
- 2020-10-20 BR BR112022008039A patent/BR112022008039A2/pt unknown
- 2020-10-20 JP JP2022524950A patent/JP7773011B2/ja active Active
- 2020-10-20 EP EP20882313.8A patent/EP4051270B1/en active Active
- 2020-10-20 EP EP26178770.9A patent/EP4778592A2/en active Pending
- 2020-10-20 AU AU2020372832A patent/AU2020372832B2/en active Active
- 2020-10-20 CN CN202080074574.7A patent/CN114599360A/zh active Pending
- 2020-10-20 WO PCT/US2020/056515 patent/WO2021086689A1/en not_active Ceased
- 2020-10-20 US US17/764,193 patent/US20220411421A1/en active Pending
- 2020-10-20 KR KR1020227017776A patent/KR20220091528A/ko active Pending
- 2020-10-20 ES ES20882313T patent/ES3075791T3/es active Active
- 2020-10-26 TW TW109137096A patent/TWI921313B/zh active
Also Published As
| Publication number | Publication date |
|---|---|
| US20220411421A1 (en) | 2022-12-29 |
| TWI921313B (zh) | 2026-04-11 |
| KR20220091528A (ko) | 2022-06-30 |
| EP4051270B1 (en) | 2026-06-10 |
| ES3075791T3 (en) | 2026-08-07 |
| CN114599360A (zh) | 2022-06-07 |
| JP2023501163A (ja) | 2023-01-18 |
| TW202128687A (zh) | 2021-08-01 |
| EP4778592A2 (en) | 2026-07-22 |
| EP4051270A1 (en) | 2022-09-07 |
| AU2020372832A1 (en) | 2022-05-12 |
| CA3152757A1 (en) | 2021-05-06 |
| JP7773011B2 (ja) | 2025-11-19 |
| AU2020372832B2 (en) | 2024-09-26 |
| WO2021086689A1 (en) | 2021-05-06 |
| EP4051270C0 (en) | 2026-06-10 |
| EP4051270A4 (en) | 2024-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2023018231A2 (es) | Restos de administración terapéutica novedosos y usos de estos | |
| BR112017016006A2 (pt) | composto, composição farmacêutica, método de tratamento de doenças e condições, uso de um composto e de uma combinação, e, combinação. | |
| BR112019011139A8 (pt) | conjugados que compreendem um agonista dual de glp/glucagon, um ligante e ácido hilaurônico | |
| BR112022026321A2 (pt) | Análogos de 1'-ciano nucleosídeo e usos dos mesmos | |
| CL2019003091A1 (es) | Terapia de combinación. | |
| CO2018002060A2 (es) | Compuestos farmacéuticos | |
| BR112015028879A8 (pt) | compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos | |
| BR112019008458A2 (pt) | 1,2,4-triazolonas 2,4,5-trisubstituídas. | |
| UY38625A (es) | Compuestos y su uso en el tratamiento del cáncer | |
| ECSP19070369A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| ECSP19083621A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| BR112023002951A2 (pt) | Compostos de fosfolipídio e usos destes | |
| NI201900098A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| BR112017010551A2 (pt) | composto, métodos para ativação de guanilato ciclase solúvel, para tratamento de uma ou mais condições selecionadas a partir de uma doença em um paciente e para tratamento de uma doença ou condição, composição farmacêutica, uso de um composto, e, medicamento. | |
| ECSP19083640A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| BR112015009504A2 (pt) | inibidores de rock | |
| BR112017026057A2 (pt) | profármacos constituídos por um conjugado linker de ácido hialurônico e agonista duplo de glp-1/glucagon | |
| BR112018074961A2 (pt) | derivados de nucleosídeo de fosforamidato como agentes anticâncer | |
| EA201791535A1 (ru) | Новое соединение 4'-тионуклеозида, а также способ его получения, его фармацевтическая композиция и применение | |
| BR112022009487A2 (pt) | Compostos antagonistas do receptor de adenosina | |
| MX2021004566A (es) | Compuestos terapeuticos. | |
| BR112018002416A2 (pt) | derivados de insulina e seus usos médicos | |
| ZA202210355B (en) | Compositions and therapeutic uses of cannabidiol | |
| EA201691570A1 (ru) | Фармацевтическая композиция, включающая диамино-гетероциклическое карбоксамидное соединение в качестве активного ингредиента | |
| MY202884A (en) | Compounds useful in hiv therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |